Trial site
The University of Osaka Hospital
Osaka, 565-0871, JapanNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche10 trials
- ABX advanced biochemical compounds GmbH1 trial
- Eli Lilly and Company1 trial
- Kite, A Gilead Company1 trial
- Nanjing IASO Biotechnology Co., Ltd.1 trial
- and 3 more
Running trials
Recruiting
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
NCT07192211· Phase 2· Rohto Pharmaceutical Co., Ltd.· Source
Contact: Sumito Okawa, Study Director
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Recruiting
TBE Zone 2 PMS in Japan
NCT07049913· W.L.Gore & Associates· Source
Contact: Hideyuki Saigusa
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Kite, A Gilead Company· Source
Recruiting
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584· Phase 3· ABX advanced biochemical compounds GmbH· Source
Contact: Alexander Hoepping, Dr.
Active, not recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991· Phase 3· Nanjing IASO Biotechnology Co., Ltd.· Source
Active, not recruiting
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: Michiko Ichii, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error